PEP-Therapy is a medical biotechnology company, which develops intracellular targeted therapies for the treatment of severe diseases, with an initial focus on cancers having high medical needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

news image

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More

Industrial Impact

APPLIED DNA ANNOUNCES RECEIPT OF LARGEST SINGLE PURCHASE ORDER FOR LINEARDNA™ TO-DATE

Applied DNA Sciences | October 11, 2022

news image

Applied DNA Sciences, Inc. a leader in PCR-based DNA technologies, announced that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a global manufacturer of in vitro diagnostics. Under the terms of the repeat order, the Company will deliver quantities of LinearDNA to the customer in the current quarter, with the full order expected to be fulfill...

Read More

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

news image

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

FierceBiotech | January 22, 2020

news image

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More
news image

Cell and Gene Therapy

TEVOGEN BIO™ FURTHER STRENGTHENS IP PORTFOLIO WITH ADDITIONAL PATENT FOR METHOD OF PREPARING ITS INVESTIGATIONAL SARS-COV-2 SPECIFIC T CELL THERAPY

Tevogen Bio | January 13, 2022

Tevogen Bio, a clinical stage biotechnology company specializing in cell and gene therapies in oncology and viral infections, announced that the U.S. Patent and Trademark Office has granted a new patent for the method of preparing COVID-19 peptide specific cytotoxic T cells for the treatment of COVID-19 infection. The patent further reinforces the biotech pioneer’s expanding IP portfolio. “Omicron’s extensive mutations and its subsequent abi...

Read More
news image

Industrial Impact

APPLIED DNA ANNOUNCES RECEIPT OF LARGEST SINGLE PURCHASE ORDER FOR LINEARDNA™ TO-DATE

Applied DNA Sciences | October 11, 2022

Applied DNA Sciences, Inc. a leader in PCR-based DNA technologies, announced that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a global manufacturer of in vitro diagnostics. Under the terms of the repeat order, the Company will deliver quantities of LinearDNA to the customer in the current quarter, with the full order expected to be fulfill...

Read More
news image

Medical

TAIWAN STARTUP MOLSENTECH ULTRA-HIGH SENSITIVITY BIOMEDICAL DETECTION TECHNOLOGY LEAPS ONTO GLOBAL STAGE

Molsentech | July 29, 2022

With its impressive achievements, Molsentech has been selected by the TTA Global Challenge sponsored by Taiwan's Ministry of Science and Technology to participate in US BIO 2022, poised to leverage its introduction to the US market as a stepping stone to leap further into the global stage. The company has successfully launched an electrical based detection system employing ultra-high sensitivity biomedical detection technology that can be applied in various disease detection from an early st...

Read More
news image

TARGOVAX PLANS CHECKPOINT COMBO TRIAL AFTER POSTING EARLY DATA ON ONCOLYTIC VIRUS

FierceBiotech | January 22, 2020

Targovax has shared data from an early-phase trial that administered ONCOS-102 to mesothelioma patients. The response rate was lower in the ONCOS-102 arm than in the control cohort, but Targovax saw positives elsewhere, leading it to outline plans to pair the drug with a checkpoint inhibitor. ONCOS-102 is an adenovírus-based cancer therapy that Targovax thinks can improve on treatment options available to patients with pleural mesothelioma, a type of cancer that affects the lining of the ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us